QUALITY BY DESIGN APPROACH: REGULATORY NEED, CURRENT, AND FUTURE PERSPECTIVE

  • AAYUSHI RAJORA Department of Quality assurance, Indore Institute of Pharmacy, Indore, Madhya Pradesh, India.
  • GURMEET CHHABRA Department of Quality assurance, Indore Institute of Pharmacy, Indore, Madhya Pradesh, India.

Abstract

Quality by design (QbD) is utilized in the event of pharmaceutical processes to create certain predefined product quality. QbD ideas unit of measurement explained in International Conference on Harmonization (ICH) pointers Q8 (R1) (Pharmaceutical development), Q9 (Quality risk management [QRM]), and Q10 (Pharmaceutical quality system). ICH Q8 (R1) guideline defines QbD as “a systematic approach to develop that begins with predefined objectives and emphasizes product and methodology, understanding, and methodology management, supported sound science and QRM.” QbD approach studied the implications of various input variables (e.g. methodology parameters, and materials) of the merchandise development methodology, on the final word product (active pharmaceutical ingredient or drug product). The late QbD approach integrates the principles of QRM, and methodology analytical technology (PAT). QbD combined with methodology analytical technology (PAT) tools modify methodology management and increase assurance that the merchandise quality attributes unit of measurement achieved consistently. An integrated and risk-based approach for review of the merchandise development methodology is also a future need of the QbD plan. Although implementing the QbD approach is not a restrictive demand, restrictive agencies to supply flexibility in their pointers for producing that unit of measurement developed by the QbD approach. Rising trends embody the growing interest in quantifying and managing the impact of raw materials’ attributes variability of methodology and product, what is more, as a result of the event of retrospective QbD approaches in complement to simple QbD. Thus, the QbD approach is also a tool for developing worth effective and quality pharmaceutical products.

Keywords: Quality by design, Risk management, International conference on harmonization guidelines, Retrospective quality by design

References

1. Woodcock J. The concept of pharmaceutical quality. Am Pharm Rev 2004;16:10-5.
2. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2006.
3. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2007.
4. Lionberger RA, Lee LS, Lee L, Raw A, Yu L × . Quality by design: Concepts for ANDAs. AAPS J 2008;10:268-76.
5. Q8 (R1): Pharmaceutical Development, Revision1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2007.
6. FDA Guidance for Industry and Review Staff: Target Product Profile a Strategic Development Process Tool (Draft Guidance); ???.
7. Patricia VA; 2007. Available from: http://www.pharmtech.com/ pharmtech/article/articleDetail.jsp?id=469915.
8. Aloka S, Robert I. Question base review (QbR) forms the platform of QbD principle. Technical 2009;15:8-10.
9. Nick T. Available from: http://www.inpharmatechnologist.com/ Processing/FDA-publishes-QbD-example-to-help-genericsfirms-file- ANDAs.
10. Callis JB, Illman DL, Kowalski BR. Process analytical chemistry. Anal Chem 1987;59:624A-37.
11. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res 2008;25:781-91.
12. Peterson JJ, Snee RD, McAllister PR, Schofield TL, Carella AJ. Statistics in pharmaceutical development and manufacturing. J Qual Technol 2009;411:111-34.
13. Nasr MM. Quality by Design (QbD) a Modern System Approach to Pharmaceutical Development and Manufacturing FDA Perspective; 2007.
14. Food and Drug Administration. Available from: http://www.fda.gov/ ohrms/dockets/ac/06/minutes/2006–4228m1.pdf.
15. US Food and Drug Administration; Guidance for Industry: Q10 Pharmaceutical Quality Systems; 2009.
16. Nasr M. Risk-based CMC Review Paradigm, Advisory Committee for Pharmaceutical Science Meeting; 2004.
17. Food and Drug Administration CDER. Guidance for Industry: Immediate Release Solid Oral Dosage Forms Scale-up and Post-approval changes: Chemistry, Manufacturing, and Controls, in vitro Dissolution Testing, and in vivo Bioequivalence Documentation; 1995.
18. Food and Drug Administration CDER. Guidance for Industry: Modified Release Solid Oral Dosage Forms Scale-up and Post-Approval Changes: Chemistry, Manufacturing, and Controls, in vitro Dissolution Testing, and in vivo bioequivalence documentation; 1997.
19. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J Pharm Biomed Anal 2010;55:848-58.
20. World Health Organization. WHO Guideline on Quality Risk Management a Draft Guidance August. Geneva: World Health Organization; 2010.
21. Gibson M. Product Optimization: Pharmaceutical Preformulation and Formulation. New York: Taylor and Francis; 2001.
22. Seely RJ, Haury J, Rathore AS, Sofer G, editors. Process Validation in Manufacturing of Biopharmaceuticals. Boca Raton, FL: Taylor and Francis; 2005. p. 13-50.
23. US Food and Drug Administration. Guidance for Industry: Q10 Quality Systems Approach to Pharmaceutical. Vol. 3. Silver Spring: US Food and Drug Administration; ???.
24. Food and Drug Administration. Guidance for Industry: PAT a Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance. Silver Spring: Food and Drug Administration; 2004.
25. Hinz DC. Process analytical technologies in the pharmaceutical industry: The FDA’s PAT initiative. Anal Bioanal Chem 2006;384:1036-42.
26. Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century a Risk-based Approach; Final Report, September. Silver Spring: Food and Drug Administration; 2004.
27. Miksinski SP. Regulatory Assessment of Applications Containing QbD Elements: FDA Perspective. Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, 27 July; 2011.
28. Jain S. Quality by design (QbD): A comprehensive understanding of implementation and challenges in pharmaceuticaldevelopment. Int J Pharm Pharm Sci 2013;6:29-35.
29. Drakulich, A. Critical challenges to implementing QbD: A Q and A with FDA. Pharm Technol 2009;33:90-4.
30. Moheb MN. Implementation of Quality by Design (QbD) Current Perspectives on Opportunities and Challenges Topic Introduction and ICH Update, Office of New Drug Quality Assessment OPS/CDER/ FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; 2014.
31. Basalious EB, El-Sebaie W, El-Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of Class II BCS drug-using polymeric surfactants and crystallization inhibitors: Development of controlled-release tablets. AAPS Pharm Sci Tech 2011;12:799-810.
32. Orlandini S, Pinzauti S, Furlanetto S. Application of QbD to development of analytical separation methods. Anal Bioanal Chem J 2013;405:2-3.
33. Marto J, Gouveia LF, Gonclaves LM. A QbD approach on starch-based nanocapsules: A promising platform for topical drug delivery. Colloids and Surfaces B Biointerfaces 2016;143:177-85.
34. Montanus J, Rozet E. Near-infrared and Raman spectroscopy as process analytical technology tools for the manufacturing of silicone-based drug reservoirs. Anal Chim Acta 2011;699:96-106.
35. Cyrus DA, Patrick JF, Muhammad JH, Sau L, Mansoor AK, Rakhi BS. Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate. J Pharm Biomed Anal 2012;25:61.
36. Visser JC, Dohmen WM, Hinrichs WL, Breitkreutz J, Frijlink HW, Woerdenbag HJ. Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films. Int J Pharm 2015;485:70-6.
37. Schweitzer M, Pohl M, Hanna-Brown M, Nethercote P, Borman PJ, Hansen G, et al. Implications and opportunities of applying qbd principles to analytical measurements. Pharm Technol 2010;34:52-9.
38. Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009;27:546-53.
39. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res 2008;25:781-91.
40. Kadam VR, Patil MP, Pawar VV, Kshirsagar S. A review on: Quality by design (QbD). Asian J Res Pharm Sci 2017;7:197-204.
41. Aksu B, Ye?en G. Global regulatory perspectives on quality by design in pharma manufacturing. Pharm Qual Des 2019;2019:19-41.
Statistics
10 Views | 17 Downloads
Citations
How to Cite
RAJORA, A., and G. CHHABRA. “QUALITY BY DESIGN APPROACH: REGULATORY NEED, CURRENT, AND FUTURE PERSPECTIVE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 6, Apr. 2021, pp. 29-35, doi:10.22159/ajpcr.2021.v14i6.33733.
Section
Review Article(s)